Qiagen N.V. Press Releases https://corporate.qiagen.com/generated by Q4Mon, 20 Jul 2026 09:02:18 -0400Copyright Q4 Inc. All rights reserved.QIAGEN highlights molecular testing solutions supporting response to growing U.S. Cyclospora outbreak065d7ac7-d61b-47ab-8347-54fad066845fhttps://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2026/QIAGEN-Highlights-Molecular-Testing-Solutions-Supporting-Response-to-Growing-U-S--Cyclospora-Outbreak/default.aspxWed, 15 Jul 2026 16:05:00 -0400QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast794a9876-e7de-4c21-a942-5e0ed81a9087https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2026/QIAGEN-N-V--to-Release-Results-for-Q2-2026-and-Hold-Webcast/default.aspxWed, 15 Jul 2026 08:48:00 -0400QIAGEN expands QIAstat-Dx bloodstream infection testing menu in Europed411c5c5-b27c-4232-8773-12e95dc750c1https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2026/QIAGEN-Expands-QIAstat-Dx-Bloodstream-Infection-Testing-Menu-in-Europe/default.aspxTue, 14 Jul 2026 16:05:00 -0400QIAGEN announces adjustment of conversion price under its US$500,000,000 Convertible Bonds due 20312fc0d071-2a96-41a1-8cb4-191a44c6339dhttps://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2026/QIAGEN-announces-adjustment-of-conversion-price-under-its-US500000000-Convertible-Bonds-due-2031/default.aspxTue, 07 Jul 2026 18:00:00 -0400QIAGEN announces adjustment of conversion price under its US$750,000,000 Convertible Bonds due 203284314ab7-da64-4d81-b47a-b1570c652e1ehttps://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2026/QIAGEN-announces-adjustment-of-conversion-price-under-its-US750000000-Convertible-Bonds-due-2032_/default.aspxTue, 07 Jul 2026 18:00:00 -0400QIAGEN announces adjustment of conversion price under its US$500,000,000 Convertible Bonds due 202720028a37-d41b-4aa7-a37d-cbcf6ccd69a1https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2026/QIAGEN-announces-adjustment-of-conversion-price-under-its-US500000000-Convertible-Bonds-due-2027/default.aspxTue, 07 Jul 2026 18:00:00 -0400QIAGEN expands QIAcuity gene expression portfolio to accelerate digital PCR adoption across research and biopharma7e789372-6302-49ed-a870-b4916c2c8665https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2026/QIAGEN-Expands-QIAcuity-Gene-Expression-Portfolio-to-Accelerate-Digital-PCR-Adoption-Across-Research-and-Biopharma/default.aspxMon, 15 Jun 2026 01:30:00 -0400QIAGEN supports infectious disease research and surveillance efforts for Bundibugyo ebolavirus outbreak48df34ab-cac5-40cb-a561-07aec175bdbdhttps://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2026/QIAGEN-Supports-Infectious-Disease-Research-and-Surveillance-Efforts-for-Bundibugyo-Ebolavirus-Outbreak/default.aspxThu, 28 May 2026 16:05:00 -0400QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows9dd7830f-f067-4311-aad3-e6c731c89a66https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2026/QIAGEN-launches-QIA-Agent-connecting-AI-driven-scientific-guidance-across-Sample-to-Insight-workflows/default.aspxWed, 20 May 2026 16:05:00 -0400QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA4fade969-58d5-4f76-99da-65dea8680617https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2026/QIAGEN-to-advance-AI-driven-drug-discovery-with-graph-based-AI-and-curated-bioinformatics-knowledge-with-NVIDIA/default.aspxTue, 19 May 2026 16:05:00 -0400